

Performance of DAPT Score and ESC Criteria for Predicting Clinical Outcomes in Chinese Patients with Acute Coronary Syndrome

Tianhua Deng , Lin Huang, Zhengli Ran, Xun Huang, Hong Li, Zhigang You

Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China

Correspondence: Zhigang You, Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, Jiangxi Province, 330006, People's Republic of China, Tel +86 13077985297, Email youzhigang_75@126.com

Purpose: The values of European Society of Cardiology (ESC) criteria and dual antiplatelet therapy (DAPT) score in the stratification of ischemic risk were assessed in this study.

Methods: A total of 489 patients with acute coronary syndrome who received DAPT at discharge between June 2020 and August 2020 were enrolled. The primary endpoint was the occurrence of major adverse cardiovascular events (MACE), which included recurrent ACS or unplanned revascularization, all-cause death, or ischemic stroke during a 27-month follow-up period.

Results: Patients with ESC-defined high-risk showed a significantly higher risk of MACE (HR 2.75, 95% CI 1.78–4.25), all-cause death (HR 2.49, 95% CI 1.14–5.43), and recurrent ACS or unplanned revascularization (HR 2.80, 95% CI 1.57–4.99) than those with ESC-defined low/medium-risk during follow-up. The results of landmark analysis showed that patients in the high-risk group had a significantly higher risk of MACE (HR 2.80, 95% CI 1.57–4.97), recurrent ACS or unplanned revascularization (HR 3.19, 95% CI 1.47–6.93) within one year, and a higher risk of MACE (HR 2.69, 95% CI 1.38–5.23) after one year. There was no significant difference in the incidence of MACE between patients with a DAPT score ≥ 2 and a DAPT score < 2 . The C-indices of ESC criteria and DAPT score for prediction of MACE were 0.63 (95% CI 0.57–0.70) and 0.54 (95% CI 0.48–0.61), respectively. The predictive value of ESC criteria for MACE was better than the DAPT score according to the DeLong test (z -statistic=2.30, $P=0.020$).

Conclusion: Patients with ESC-defined high-risk had a higher risk of MACE compared to those with ESC-defined low/medium-risk. The discriminant ability of the ESC criteria was better than the DAPT score for MACE. The ESC criteria demonstrated moderate discriminatory capacity of MACE in ACS patients treated with DAPT.

Keywords: acute coronary syndrome, ESC criteria, DAPT score, platelet inhibitors, clinical outcome

Introduction

The 2020 European Society of Cardiology (ESC) guidelines on non-ST segment elevation acute coronary syndrome (NSTEMI-ACS)¹ recommend 12-month dual antiplatelet therapy (DAPT) for patients with NSTEMI-ACS, which includes aspirin and a potent P2Y₁₂ receptor inhibitor (ticagrelor or prasugrel). However, under the standard antiplatelet strategy, the risk of residual ischemia in ACS patients remains high.² Some large randomized trials have demonstrated that after 12 months of DAPT, adding a second antithrombotic agent (clopidogrel,³ prasugrel,⁴ ticagrelor,^{5–7} or rivaroxaban⁸) to aspirin can further reduce the incidence of all-cause death, myocardial infarction, and stroke. Therefore, according to the 2020 ESC guidelines, an intensified strategy for prolonging DAPT duration should be considered for patients with a high risk of ischemic events.¹

However, distinguishing patients who might profit from an intensified strategy while avoiding the strategy in low-risk patients continues to pose a great challenge in current clinical practice. In order to identify patients with high thrombosis risk from NSTEMI-ACS patients, the ESC guidelines¹ proposed new criteria for thrombosis risk, consisting of a binary approach that includes one major criterion and multiple risk enhancers. These criteria have not yet been externally validated in real-world populations.

The DAPT score is a clinical decision tool that helps distinguish patients expected to benefit or harm from continuing DAPT beyond 1 year. Yeh et al⁹ found that for patients with a DAPT score ≥ 2 , extending the DAPT strategy reduced ischemic events without increasing the risk of major bleeding, which means that the DAPT score could help clinicians identify patients suitable for longer DAPT. However, in the real world, the discriminant ability of the DAPT score is controversial.^{10–15}

This study evaluated the predictive value of ESC criteria and DAPT scores in patients with ACS.

Methods

Study Population

A total of 489 patients admitted to the Second Affiliated Hospital of Nanchang University for ACS who received DAPT at discharge were recruited between June and August 2020 (Figure 1). The inclusion criteria were as follows: (1) diagnosed with ACS (including unstable angina pectoris, ST-segment elevation myocardial infarction (STEMI), and non-ST segment elevation myocardial infarction) on admission; (2) Age ≥ 18 years old; (3) Who received one or more coronary angiography (CAG) during hospitalization and survived to discharge. The exclusion criteria were: (1) Complicated with a life-threatening malignant tumor; (2) Died during hospitalization or within 10 days after discharge; (3) Refused CAG and further drug treatment during hospitalization; (4) Diagnosed with stable angina pectoris or myocardial bridge; and (5) Did not use DAPT at discharge. Finally, 489 patients were included.

Risk Stratification

The details of clinical data, including clinical characteristics, history of diseases, angiographic data, biochemistry, and medications, were retrospectively collected from the hospital's electronic database. Multivessel disease was defined as coronary angiography showing stenosis $\geq 50\%$ in three-vessel coronary systems. The definition of complex coronary artery disease included severe stenosis of the left main trunk (diameter stenosis $\geq 50\%$) or severe stenosis of three large coronary arteries (diameter stenosis $\geq 70\%$), with or without the involvement of the proximal anterior descending branch.




Figure 1 The flowchart of study population selection.

According to the ESC criteria, the high ischemic risk was defined as complex coronary artery disease and at least 1 criterion, which included eight risk enhancers (diabetes mellitus requiring medication, history of recurrent MI (myocardial infarction), multivessel CAD (coronary artery disease), polyvascular disease, premature or accelerated CAD, concomitant systemic inflammatory disease, and CKD with eGFR (estimated glomerular filtration rate) 15–59 mL/min/1.73 m²), and five technical aspects (history of stent thrombosis, history of complex revascularization, at least 3 stents implanted, at least 3 lesions treated, and total stent length >60 mm). The moderate ischemic risk was defined as non-complex coronary artery disease and at least 1 criterion (CKD with eGFR 15–59 mL/min/1.73 m², history of recurrent MI, diabetes mellitus requiring medication, and polyvascular disease). The DAPT score consisted of 9 variables, including age (0 points for age <65 years, –1 points for 65 to <75 years, and –2 points for ≥75 years), cigarette smoking, diabetes mellitus, MI at presentation, prior PCI or prior MI, paclitaxel-eluting stent, stent diameter <3 mm (1 point each), congestive heart failure or left ventricular ejection fraction <30%, and vein graft stent (2 points each). Patients with a score ≥2 had a higher risk of ischemic events than those with a score <2, according to the DAPT score. The predictive values of ESC criteria and DAPT score were compared to further examine the clinical performance of the ESC criteria. Nine variables calculated the DAPT score. In the high score group (score ≥2), prolonged DAPT was associated with reduced ischemic events when compared with the low score group (score <2).

Endpoint Definition and Follow-Up

Follow-up data were obtained through phone contact or medical records. The primary endpoint was defined as a major adverse cardiovascular event (MACE), which included all-cause death, recurrent ACS or unplanned revascularization (UR), and ischemic stroke. All patients were followed up for at least 24 months unless end events were observed. Recurrent ACS was defined as new-onset NSTEMI-ACS and STEMI. UR was defined as unplanned readmission for percutaneous transluminal coronary angioplasty (PTCA), PCI, or coronary artery bypass grafting (CABG) driven by coronary ischemia. The diagnosis of ischemic stroke was based on signs from neuroimaging studies and symptoms of the nervous system.

Statistical Analysis

Continuous variables with normal and skewed distribution were analyzed using Student's *t*-test and Kruskal–Wallis test, respectively. Categorical variables were analyzed using the χ^2 test. According to ESC criteria, patients were divided into high and low/medium-risk groups. Kaplan–Meier method and Cox proportional hazard analysis were performed to evaluate the correlation between the prediction models and the occurrence of adverse events. Additionally, landmark analyses of the Kaplan–Meier estimates of clinical outcomes at one year were performed. Receiver operating characteristic (ROC) curves were used to evaluate the discriminative capacities of the prediction models, and C-statistics > 0.6 was considered acceptable. $P < 0.05$ represented statistical significance. All statistical analyses were performed using EmpowerStats (www.empowerstats.com).

Results

Patients in the ESC-defined high-risk group were older and had a higher burden of comorbidity, including stroke, PAD, heart failure, hypertension, diabetes, previous myocardial infarction, and multiple coronary artery disease than patients in the low/medium-risk group. In addition, higher creatinine levels, lower ejection fractions, and lower eGFR levels were observed in high-risk patients. Considering information about the index procedure, most high-risk patients had the three-vessel disease (89.1%), while those with low/moderate risk had single- or two-vessel disease (87.9%). Left main disease, CTO, stent size < 3 mm, >3 stents, and total stent length > 60 mm were more common in high-risk patients (Table 1). In addition, drug-eluting stents (such as everolimus-eluting stent and rapamycin-eluting stents) were used in all patients undergoing coronary stent implantation.

According to the ESC criteria, 183 (37.4%) patients were classified as high-risk, 97 (19.8%) as medium-risk, and 209 (42.7%) as low-risk. There were 267 patients (54.6%) with a DAPT score ≥2 and 222 patients (45.4%) with a DAPT score < 2. The number of patients satisfied with ESC high thrombotic risk and a DAPT score ≥2 was 113 (23.1%).

Table 1 Baseline Characteristics of the Two Groups

	Low/Moderate Thrombotic Risk (n=306)	High Thrombotic Risk (n=183)	P*
Admission information			
Male, n (%)	212 (69.3)	131 (71.6)	0.590
Age (years)	63.2±11.4	67.7±11.0	<0.001
STEMI, n (%)	79 (25.8)	38 (20.8)	0.205
LVEF (%)	59.8±9.0	55.7±10.7	<0.001
Smoking, n (%)	85 (27.8)	51 (27.9)	0.983
History of disease, n (%)			
Stroke	17 (5.6)	31 (16.9)	<0.001
Peripheral vascular disease	5 (1.6)	13 (7.1)	0.002
Hypertension	166 (54.2)	140 (76.5)	<0.001
Diabetes mellitus	82 (26.8)	69 (37.7)	0.012
Concomitant systemic inflammatory disease	2 (0.7)	1 (0.5)	0.883
Previous PCI	50 (16.3)	54 (29.5)	0.001
Previous CABG	1 (0.3)	2 (1.1)	0.294
CKD	13 (4.2)	10 (5.5)	0.539
Heart failure	3 (1.0)	19 (10.4)	<0.001
OMI	19 (6.2)	30 (16.4)	<0.001
Atrial fibrillation	14 (4.6)	8 (4.4)	0.916
Laboratory test			
Uric acid (mmol/L)	375.6±112.5	391.6±120.4	0.138
Creatinine (μmol/L) [IQR]	77.6 (64.3–91.2)	83.8 (71.3–104.0)	<0.001
eGFR (mL/min/1.73m ²)	83.8±23.7	73.7±27.1	<0.001
Medication, n (%)			
Statin	302 (98.7)	182 (99.5)	0.655
Ticagrelor	203 (66.3)	126 (68.9)	0.567
β-blocker	290 (94.8)	174 (95.1)	0.880
ACEI/ARB	180 (58.8)	120 (65.6)	0.138
CCB	65 (21.2)	31 (16.9)	0.246
Angiography characteristics, n (%)			
1-vessel disease	143 (46.7)	2 (1.1)	<0.001
2-vessel disease	126 (41.2)	18 (9.8)	<0.001
3-vessel disease	37 (12.1)	163 (89.1)	<0.001
Left main disease	5 (1.6)	45 (24.6)	<0.001
In-stent restenosis	2 (3.9)	17 (9.3)	0.015
CTO	16 (5.2)	41 (22.4)	<0.001
Patients with PCI	256 (83.7)	170 (92.9)	0.003
Stent diameter <3 mm	103 (33.7)	114 (62.3)	<0.001
≥3 stents implanted	39 (12.7)	102 (55.7)	<0.001
Total stent length >60 mm	77 (25.2)	120 (65.6)	<0.001

Notes: Data are shown as the mean ± standard deviation, median value (interquartile range), or percentage when appropriate. *Student's t-test, Kruskal–Wallis test or χ^2 test was done when appropriate.

Abbreviations: STEMI, ST-segment elevation myocardial infarction; LVEF, Left ventricular ejection fractions; PCI, Percutaneous coronary intervention; CABG, Coronary angioplasty bypass grafting; CKD, Chronic kidney disease; OMI, Old myocardial infarction; eGFR, Estimated glomerular filtration rate; ACEI, angiotensin converting enzyme inhibitors; ARB, Angiotensin receptor blocker; CCB, Calcium channel blocker; CTO, Chronic total occlusion.

Clinical Outcomes

The median follow-up time was 27.2 months. The incidence and relative risks of end events are listed in [Table 2](#). The event rates of MACE, all-cause death, recurrent ACS or UR, and ischemic stroke in the high-risk group were 51 (27.9%), 15 (8.2%), 29 (15.8%), and 7 (3.8%), respectively. In the low/moderate group, the event rates of MACE, all-cause death,

Table 2 Clinical Outcomes at Follow-Up Time

End Point		Event Rate, %	HR (95% CI)	P*
MACE	ESC criteria	Low to moderate	34 (11.1)	Ref
		High	51 (27.9)	2.75 (1.78–4.25)
	DAPT score	<2	32 (14.4)	Ref
		≥2	53 (19.9)	1.43 (0.92–2.22)
All cause death	ESC criteria	Low to moderate	11 (3.6)	Ref
		High	15 (8.2)	2.49 (1.14–5.43)
	DAPT score	<2	14 (6.3)	Ref
		≥2	12 (4.5)	0.73 (0.34–1.59)
Recurrent ACS or UR	ESC criteria	Low to moderate	19 (6.2)	Ref
		High	29 (15.8)	2.80 (1.57–4.99)
	DAPT score	<2	16 (7.2)	Ref
		≥2	32 (12.0)	1.73 (0.95–3.15)
Stroke	ESC criteria	Low to moderate	4 (1.3)	Ref
		High	7 (3.8)	3.24 (0.94–11.08)
	DAPT score	<2	2 (0.9)	Ref
		≥2	9 (3.4)	3.94 (0.85–18.23)

Notes: Data are shown as number and percentage. *Univariate COX regression analysis was done.

Abbreviations: MACE, Major adverse cardiovascular events; ACS, Acute coronary syndrome; UR, unplanned revascularization.

recurrent ACS or UR, and ischemic stroke were 34 (11.1%), 11 (3.6%), 19 (6.2%), and 4 (1.3%), respectively. Patients with ESC-defined high-risk had a significantly higher risk of MACE (HR 2.75, 95% CI 1.78–4.25, $P < 0.001$), all-cause death (HR 2.49, 95% CI 1.14–5.43, $P=0.021$), and recurrent ACS or UR (HR 2.80, 95% CI 1.57–4.99, $P < 0.001$) than patients with ESC-defined low/moderate-risk. The risk of stroke was similar between the two groups, which is consistent with the results of multivariate COX regression analysis (Table S1).

There was no significant difference in the risk of MACE (HR 1.43, 95% CI 0.92–2.22, $P=0.107$), all-cause death (HR 0.73, 95% CI 0.34–1.59, $P=0.443$), recurrent ACS or UR (HR 1.73, 95% CI 0.95–3.15, $P=0.073$), and ischemic stroke (HR 3.94, 95% CI 0.85–18.23, $P=0.079$) between patients with DAPT score ≥ 2 and those with DAPT score < 2 .

Landmark Analysis

Compared with low/moderate patients, patients with ESC-defined high-risk showed significantly higher rates of MACE (HR 2.80, 95% CI 1.57–4.97, $P < 0.001$) (Figure 2) and recurrent ACS or UR (HR 3.19, 95% CI 1.47–6.93, $P=0.003$) within one year and higher rates of MACE (HR 2.69, 95% CI 1.38–5.23, $P=0.003$) after one year (Figure S1). Conversely, the patients with DAPT scores ≥ 2 and those with DAPT scores < 2 showed similar incidence of clinical outcomes.

Comparison of the Predictive Performance of ESC Criteria and DAPT Score

The C-statistic of the ESC criteria and DAPT score for prediction of MACE were 0.63 (95% CI 0.57–0.70) and 0.54 (95% CI 0.48–0.61), respectively (Figure 3). The sensitivity and specificity of the ESC criteria were 0.60 and 0.67, respectively. In sensitivity analyses, by separating patients with low/medium risk and DAPT score < 2 , patients with ESC-defined high-risk and DAPT score ≥ 2 were defined as high-risk patients, while other patients were classified as medium/low-risk patients, improving the specificity of predicting MACE events (C index:0.60, 95% CI 0.53–0.67, sensitivity:0.40, specificity:0.80) (Table 3). As shown in Table 4, the discriminative power ESC criteria were better than the DAPT score (z statistic=2.300, $P=0.020$).




Figure 2 Landmark analysis of the Kaplan-Meier estimates of MACE within one year and after one year. **(A)** MACE event rates in the ESC-defined high-risk and ESC-defined low/moderate-risk groups and landmark analysis within and after one year. **(B)** MACE event rates in the DAPT score ≥ 2 and DAPT score < 2 groups and landmark analysis within and after one year.




Figure 3 The receiver operating characteristic (ROC) curve of the ESC criteria and DAPT score for MACE in patients with ACS.

Subgroup Analysis

The risk factors in the ESC criteria were not evaluated in the subgroup analysis. The results of the interaction and subgroup analyses between the two groups according to sex, age, smoking, hypertension, STEMI at admission, and PCI

Table 3 Areas Under the Receiver Operating Characteristic Curves for ESC Risk Criteria, DAPT Score, and the Combination of ESC Risk Criteria and DAPT Score in Identifying MACE

	AUC (95% CI)	P-value	Sensitivity	Specificity
ESC risk criteria	0.637 (0.571–0.703)	<0.001	0.600	0.673
DAPT score	0.547 (0.480–0.614)	0.174	0.624	0.470
ESC risk criteria combine DAPT score	0.602 (0.532–0.672)	0.003	0.400	0.804

Abbreviation: AUC, Area under curve.

Table 4 To Compare the Ability of ESC Risk Criteria, DAPT Score to Predict MACE


	Comparison	z	P*
All patients	DAPT vs ESC criteria	2.300	0.020

Note: *The DeLong test was done.

during hospitalization are shown in Figure 4. The results showed that the correlation between ESC criteria and the risk of MACE was consistent among the different subgroups. No significant interaction was observed in this analysis.

Discussion

Over the past few decades, the development of percutaneous coronary intervention (PCI) technology and drug therapy significantly decreased the short-term risk of fatal events in patients with ACS.¹⁶ Currently, DAPT de-escalation, potent P2Y12 inhibitor monotherapy, and conventional DAPT are used as dominant strategies to reduce the risk of bleeding.^{17–19} However, the heterogeneity of the ACS population is high, and many patients are at a high risk of residual ischemia.²⁰ Thus, a single treatment strategy does not apply to all patients. Antithrombotic therapy should combine the clinical characteristics of the patients to formulate individualized strategies in patients with ACS. Accurate identification of patients with a high risk of ischemic events is crucial in treatment allocation.

**Figure 4** Subgroup analysis of the prognostic value of the ESC criteria in different subgroups for MACE.

New thrombotic risk criteria for patients with chronic coronary syndromes (CCS) have been proposed by 2019 ESC guidelines.²¹ Also, a study conducted in Western Denmark²² further examined the predictive value of these criteria, finding that the incidence of MACE was significantly higher in patients with ESC-defined high-risk (HR 1.9 95% CI 1.8 ~ 1.9), while the C-statistic for prediction of MACE was 0.58 (95% CI 0.57–0.58).

Compared with the 2019 ESC thrombotic risk criteria for CCS patients, the 2020 criteria include more risk enhancers, such as concomitant systemic inflammatory diseases, premature or accelerated CAD, and technical aspects. Also, there are different major criteria between the two. The present study evaluated the discriminative power of the 2020 ESC criteria for predicting MACE during 27 months of follow-up and further verified the ability of the criteria to stratify ischemic risk within one year and after one year by landmark analysis. Our results showed that the ESC criteria could determine ischemic risk in patients with ACS within one year and beyond. By stratifying the ischemic risk of ACS patients within one year, it is possible to identify patients at high risk of ischemia who are not eligible for the DAPT de-escalation strategy. By stratifying the ischemic risk of patients one year after the occurrence of ACS, clinicians can identify patients who could benefit the most from an intensified strategy while avoiding unnecessary treatment in patients at low risk.

By comparing the baseline characteristics of the two groups, we found that high-risk patients had more concomitant diseases (including stroke, PAD, hypertension, and diabetes), more complex diseased vessels, and more complex revascularization. Patients in the high-risk group had more ESC criteria-defined risk factors than patients in the low/moderate risk group (Table S2), which may explain the higher incidence of MACE in the high-risk group.

In the present study, the patients with DAPT scores ≥ 2 had similar incidence of clinical outcomes as those patients with DAPT scores < 2 . The C-statistic of the DAPT score for the prediction of MACE was 0.54 (95% CI 0.48–0.61), which means that the DAPT score could not fully identify the risk of MACE.

DAPT score may not identify patients with a higher incidence of MACE who could benefit from extended treatment with a second antithrombotic agent. Considering that the original study⁹ of DAPT score did not include all-cause death as the study endpoint, the association between DAPT score and ischemic events, including recurrent ACS or UA, and ischemic stroke, was exploratorily evaluated. In the exploratory analysis, the risk of ischemic events was significantly increased in patients with a DAPT score ≥ 2 at follow-up (HR 1.97, 95% CI 1.13–3.43) and after one year (HR 2.40, 95% CI 1.01–5.72). The C-statistic for predicting ischemic events was 0.58 (95% CI 0.51–0.66), indicating a low discriminative capacity.

The validity of the DAPT score has been controversial since the start. Some studies have successfully verified the ability of DAPT scores to identify patients at a higher risk of ischemic events.^{23,24} Others have found that the DAPT score could not adequately discriminate between ischemic and bleeding risks, and the score and its decision rule may not be generalizable to real-world populations.¹⁴ A study that verified the DAPT score in the Chinese ACS population also reported the unsatisfactory ability of the DAPT score to discriminate ischemic events.¹³ Several reasons may explain why the DAPT score did not fully distinguish the risk of adverse events in this study. First, Asians have significantly smaller total vessel diameters than Caucasians. It has been verified that Asians have smaller dimensions of all proximal coronary arteries than Caucasians, regardless of age, sex, or body size.^{25,26} This difference explains the smaller stent diameter in Asians, which weakens the value of stent diameter < 3 mm and acts as a positive predictor of DAPT score, resulting in more patients being classified as having a high ischemia risk. Second, the use of paclitaxel-eluting stents greatly contributed to the parameters of DAPT scores. Yet, with the widespread use of newer generations of stents, paclitaxel-eluting stents are no longer applied in current clinical practice, leading to a different distribution of DAPT scores between this study and the DAPT study. Third, older age is an important risk enhancer for all-cause mortality.²⁷ However, it is regarded as a negative predictor of the DAPT score, which disturbs the relationship between the DAPT score and MACE. Finally, the relatively small sample size in this study may lack sufficient test efficiency.

In the present study, approximately 1/3 of the patients were classified as having a high thrombotic risk according to ESC criteria, and these patients showed a higher incidence of MACE, recurrent ACS or UA, and all-cause death during 27 months of follow-up. The C-statistic of the ESC criteria for the prediction of MACE was 0.63 (95% CI 0.57–0.70), showing moderate discriminatory capacity during a period of 27 months. It was less likely to perform better for simple risk criteria because of the high heterogeneity of the ACS population. On the other hand, risk scores with more clinical variables, such as the PRAISE score,²⁸ which is based on artificial intelligence computations and contains 25 clinical variables, have also been proposed. The score showed accurate discriminative capabilities for predicting all-cause death

and myocardial infarction, which may help guide clinical decision-making. However, the complexity of the PRAISE score may hinder its clinical application.

Study Limitations

The present study has some limitations. First, this was a retrospective, observational study. Although subgroup and multivariate analyses were applied, unadjusted confounding factors were difficult to avoid. Second, although 12-month DAPT is recommended as a standard treatment strategy for patients with ACS according to Chinese guidelines, and most patients followed the recommendation, accurate information about the duration of DAPT was unavailable, which could affect the risk of MACE in patients. In addition, the sample size was small and was obtained from a single center. Therefore, the results of this study need to be further validated by large trial study.

Conclusions

DAPT score could not stratify the MACE risk of patients with ACS. Compared with low-risk patients, patients with ESC-defined high-risk had an increased risk of MACE within one year and beyond. The ESC criteria had moderate discriminative ability for MACE in Asian patients with ACS. Considering the criteria's simplicity, reliability, and discriminating ability, they have certain prospects in clinical practice.

Ethics Approval

This study was approved by the Institutional Review Board of the Second Affiliated Hospital of Nanchang University. Written informed consent was acquired from all participants for their participation in our study. We confirmed that our study complies with the Declaration of Helsinki.

Consent to Participate

Informed consent was obtained from all individual participants included in the study.

Funding

This work was supported by the Jiangxi Provincial Natural Science Foundation of China (NO.20181BAB205083). The source of funding did not have any impact on study design; analysis and interpretation of data or writing of the manuscript.

Disclosure

The authors have no relevant financial or non-financial interests to disclose for this work.

References

1. Collet J, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2021;42(14):1289–1367.
2. Chan PYD, Ten BJ. Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options. *Neth Heart J*. 2022;30(1):38–46. doi:10.1007/s12471-021-01604-4
3. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N Engl J Med*. 2014;371(23):2155–2166. doi:10.1056/NEJMoa1409312
4. Garratt KN, Weaver WD, Jenkins RG, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS liberty paclitaxel-eluting coronary stent placement. *Circulation*. 2015;131(1):62–73. doi:10.1161/CIRCULATIONAHA.114.013570
5. Bansilal S, Bonaca MP, Cornel JH, et al. Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease. *J Am Coll Cardiol*. 2018;71(5):489–496. doi:10.1016/j.jacc.2017.11.050
6. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med*. 2015;372(19):1791–1800. doi:10.1056/NEJMoa1500857
7. Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a Phase 3, placebo-controlled, randomised trial. *Lancet*. 2019;394(10204):1169–1180. doi:10.1016/S0140-6736(19)31887-2
8. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet*. 2018;391(10117):205–218. doi:10.1016/S0140-6736(17)32458-3

9. Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. *JAMA*. 2016;315(16):1735–1749. doi:10.1001/jama.2016.3775
10. Veron-Esquivel D, Batiz-Armenta F, Cazares-Diazleal AC, et al. Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction. *Hell J Cardiol*. 2019;60(5):296–302. doi:10.1016/j.hjc.2018.05.007
11. Kim M, Park KW, Lee HS, et al. The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents. *Catheter Cardiovasc Interv*. 2021;98(3):E332–E341. doi:10.1002/ccd.29682
12. Yoshikawa Y, Shiomi H, Watanabe H, et al. Validating utility of dual antiplatelet therapy score in a large pooled cohort from 3 Japanese percutaneous coronary intervention studies. *Circulation*. 2018;137(6):551–562. doi:10.1161/CIRCULATIONAHA.117.028924
13. Song L, Guan C, Yan H, et al. Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations. *Catheter Cardiovasc Interv*. 2018;91(S1):573–581. doi:10.1002/ccd.27468
14. Ueda P, Jernberg T, James S, et al. External validation of the DAPT score in a nationwide population. *J Am Coll Cardiol*. 2018;72(10):1069–1078. doi:10.1016/j.jacc.2018.06.023
15. Witberg G, Zusman O, Bental T, et al. Validation of the DAPT score in real-world patients undergoing coronary stent implantation. *Int J Cardiol*. 2020;300:99–105. doi:10.1016/j.ijcard.2019.08.044
16. Puymirat E, Simon T, Cayla G, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French registry of acute ST-elevation or non-ST-elevation myocardial infarction) 1995 to 2015. *Circulation*. 2017;136(20):1908–1919. doi:10.1161/CIRCULATIONAHA.117.030798
17. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. *JAMA*. 2019;321(24):2414–2427. doi:10.1001/jama.2019.8145
18. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. *N Engl J Med*. 2019;381(21):2032–2042. doi:10.1056/NEJMoa1908419
19. Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet*. 2018;392(10151):940–949. doi:10.1016/S0140-6736(18)31858-0
20. Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian study). *Eur Heart J*. 2010;31(22):2755–2764. doi:10.1093/eurheartj/ehq326
21. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41(3):407–477. doi:10.1093/eurheartj/ehz425
22. Würtz M, Olesen KKW, Mortensen MB, et al. Dual antithrombotic treatment in chronic coronary syndrome: European society of cardiology criteria vs. CHADS-P2A2RC score. *Eur Heart J*. 2022;43(10):996–1004. doi:10.1093/eurheartj/ehab785
23. Chichareon P, Modolo R, Kawashima H, et al. DAPT score and the impact of ticagrelor monotherapy during the second year after PCI. *JACC Cardiovasc Interv*. 2020;13(5):634–646. doi:10.1016/j.jcin.2019.12.018
24. Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. *J Am Coll Cardiol*. 2016;67(21):2492–2502. doi:10.1016/j.jacc.2016.03.485
25. Dhawan J, Bray CL. Are Asian coronary arteries smaller than Caucasian? A study on angiographic coronary artery size estimation during life. *Int J Cardiol*. 1995;49(3):267–269. doi:10.1016/0167-5273(95)02315-N
26. Skowronski J, Cho I, Mintz GS, et al. Inter-ethnic differences in normal coronary anatomy between Caucasian (Polish) and Asian (Korean) populations. *Eur J Radiol*. 2020;130:109185. doi:10.1016/j.ejrad.2020.109185
27. Man C, Xiang S, Fan Y. Frailty for predicting all-cause mortality in elderly acute coronary syndrome patients: a meta-analysis. *Ageing Res Rev*. 2019;52:1–6. doi:10.1016/j.arr.2019.03.003
28. D'Ascenzo F, De Filippo O, Gallone G, et al. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. *Lancet*. 2021;397(10270):199–207. doi:10.1016/S0140-6736(20)32519-8

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>